 |
Vol.43 No.7 contents | Japanese/English |
 | Full Text of PDF (155K) Article in Japanese |
- -
Complete Responses Treated by Irinotecan Chloride Combination Chemotherapy
Shinzoh Kudoh1, Naruo Yoshimura11Respiratory Medicine, Osaka City University, Medical School
Two complete response (CR) cases were presented, treated by irinotecan chloride combination chemotherapy. One was 47-year old female with cT4N3M0 adenocarcinoma of lung. She was treated by 4 courses of cisplatin and irinotecan combination chemotherapy and became a CR. She has now a progression-free survival 2 years and a month after beginning of the treatment. Another case was 51-year old male with cT2N2M1 small cell carcinoma of lung. He was treated by 4 courses of cisplatin, irinotecan and etoposide combination chemotherapy and became a CR. He also has now a progression-free survival 3 years and 7 months after beginning of the treatment. CR rate of cisplatin and irinotecan combination chemotherapy against advanced non-small cell lung cancer is 1.6% and it has become around 10% of 2-year survival rate by platinum and new anticancer agent treatment. CR rate of irinotecan combination chemotherapy against extensive stage small cell lung cancer is now 10 to 20% and 2 and 3-year survival rate are around 20% and near 10%, respectively. There are only few cases of CR and long term survivors in patients with advanced lung cancer treated by chemotherapy. In near future, it is expected to better outcome of advanced lung cancer by introducing new agents including molecular targeted therapy.
key words: Irinotecan, Complete response, Advanced lung cancer
JJLC 43 (7): 850-856, 2003
